Tag: G1 Therapeutics

G1 Therapeutics’ Phase 3 trial of trilaciclib for metastatic triple negative breast cancer continues as planned

businessnewstoday- February 13, 2024

In a significant update for the oncology community, G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage company specializing in cancer treatment, announced the continuation of its ... Read More

G1 Therapeutics gets Cosela FDA approval to reduce chemotherapy-induced bone marrow suppression

pharmanewsdaily- February 15, 2021

G1 Therapeutics has bagged approval for Cosela (trilaciclib) from the US Food and Drug Administration (FDA) for reducing bone marrow suppression caused by chemotherapy. Cosela ... Read More